Migraine Screening Recommended Annually for Women & Girls | AHS Guidance

The American Headache Society (AHS) is now recommending annual migraine screening as a standard component of preventive healthcare for girls and women, extending from adolescence through menopause. This recent guidance, released in early March 2026, aims to address the significant underdiagnosis and undertreatment of migraine in this population. Migraine is a prevalent neurological condition, and proactive screening is intended to enable earlier diagnosis and more effective management.

The Scope of the Problem: Why Routine Screening?

Despite its high prevalence, migraine remains a significantly underdiagnosed condition. The AHS position statement, developed following a review of published literature and consensus among experts, highlights that migraine’s substantial negative impacts on quality of life and economic productivity warrant a shift towards routine screening. The statement emphasizes that migraine fulfills established criteria for conditions where screening is appropriate due to its high prevalence, the significant morbidity it causes, and the substantial economic and social costs associated with it. Research published in PubMed details the development of this position statement and the rationale behind it.

Migraine incidence and prevalence are particularly high among girls and women, especially during adolescence and throughout the menopausal transition. This makes this demographic a key focus for preventative care. The AHS notes that valid and reliable diagnostic screening tools, such as ID Migraine, are available, alongside effective treatments that can reduce migraine symptoms and improve overall well-being.

What Does This Mean for Women’s Healthcare?

Currently, many women may suffer for years with debilitating headaches before receiving a proper diagnosis. This delay can lead to lost productivity, reduced quality of life, and potentially inappropriate or ineffective treatments. The AHS recommendation suggests that incorporating a yearly diagnostic screening for migraine into routine women’s healthcare visits could significantly improve these outcomes. This isn’t about diagnosing every headache as migraine. it’s about identifying those individuals who meet the criteria for further evaluation and management.

The recommendation doesn’t specify a single screening method, leaving room for clinicians to utilize tools and approaches best suited to their practice and patient population. Yet, the AHS highlights the availability of validated screening tools like ID Migraine, which can help identify individuals at higher risk of migraine. The full position statement published in the Headache Journal provides further detail on the methodology used to reach this recommendation.

Understanding Migraine: Beyond Just a Headache

It’s important to understand that migraine is more than just a severe headache. It’s a complex neurological condition that can manifest with a variety of symptoms, including throbbing pain, nausea, vomiting, sensitivity to light and sound, and visual disturbances. These symptoms can significantly interfere with daily activities and overall quality of life. Migraine is thought to involve changes in brain activity and blood flow, and genetic factors can play a role in susceptibility.

There are different types of migraine, including migraine with aura (where visual or sensory disturbances precede the headache) and migraine without aura. Diagnosis typically involves a detailed medical history and physical examination. Although there is no single cure for migraine, a variety of treatments are available, including medications to prevent attacks and medications to relieve symptoms during an attack. Lifestyle modifications, such as managing stress and maintaining a regular sleep schedule, can also be helpful.

The Process Behind the Recommendation and What to Expect

The AHS recommendation wasn’t arrived at lightly. The development of this position statement followed a rigorous process established by the AHS Guidelines Committee. This included a thorough review of the published literature to determine if migraine met the criteria for justified disease screening, guidance on appropriate screening tools, and identification of subpopulations where screening is particularly indicated. The statement was then reviewed and approved by the AHS Board of Directors.

What comes next is implementation. Healthcare providers will demand to integrate migraine screening into their existing women’s health protocols. This may involve training staff on the leverage of screening tools and educating patients about the importance of early diagnosis and treatment. Medscape’s coverage of the recommendation notes that this is a significant step towards improving migraine care for women.

Looking Ahead: Ongoing Research and Refinement

The AHS recommendation is likely to spur further research into the effectiveness of routine migraine screening. Studies will be needed to evaluate the impact of screening on diagnosis rates, treatment initiation, and patient outcomes. It’s also possible that the AHS will revisit and refine its recommendation as new evidence emerges. The field of headache medicine is constantly evolving, and ongoing research is essential to improving our understanding and treatment of migraine.

For women experiencing frequent or severe headaches, it’s important to discuss these symptoms with a qualified healthcare professional. Early diagnosis and appropriate management can significantly improve quality of life and prevent the long-term complications associated with untreated migraine. Staying informed about the latest recommendations and research is also crucial for making informed decisions about your health.